I-Mab stock price target raised to $8 from $6 at Brookline Capital

I-Mab (NASDAQ:IMAB) has seen its price target raised by Brookline Capital to $8.00 and Buy rating reiterated by H.C. Wainwright, following highly positive Phase 1b data for its lead cancer drug, givastomig, which demonstrated an 83% objective response rate in metastatic gastric cancer. This clinical success, coupled with a strengthened balance sheet from a recent capital raise and a strategic acquisition securing key drug rights, underscores growing analyst confidence in the company's oncology pipeline and future prospects, despite its substantial 429% year-to-date return.

Analysis

I-Mab (IMAB) is exhibiting strong positive momentum driven by significant clinical and corporate milestones for its lead oncology asset, givastomig. Analyst confidence is rising, evidenced by Brookline Capital Markets increasing its price target to $8.00 from $6.00 and H.C. Wainwright reiterating a Buy rating with a $7.00 target. This optimism is primarily fueled by compelling Phase 1b trial results where givastomig, in combination with nivolumab and chemotherapy, achieved an 83% objective response rate in treating metastatic gastric cancers. The company's operational execution is also notable, with patient enrollment for dose expansion cohorts completed ahead of schedule, setting up a key data catalyst in Q1 2026. Financially, I-Mab's position has been fortified by a recent capital raise and is reflected in a robust current ratio of 22.8. Furthermore, the strategic acquisition of Bridge Health Biotech secures crucial upstream rights to the CLDN18.2 parental antibody, eliminating future royalty obligations and enhancing the long-term commercial profile of givastomig. Despite a 429% year-to-date return, the current price of $4.41 trades at a considerable discount to these revised analyst targets.

Key Decisions for Investors

• Given the compelling 83% objective response rate in a key trial and a current stock price significantly below new analyst targets of $7.00-$8.00, investors may view the stock as having further upside potential despite its substantial rally.
• The primary forward-looking catalyst to monitor is the topline data from the givastomig dose expansion cohorts, expected in Q1 2026, which represents a major inflection point for the company's valuation.
• The improved financial stability from a recent capital raise and the strategic acquisition eliminating future royalty payments have materially de-risked the asset, strengthening the long-term investment case.
• While fundamentals are improving, the stock's 429% year-to-date gain heightens the risk of volatility and profit-taking, suggesting that any new or existing positions should be managed with this context in mind.